RBCK1 regulates the progression of ER-positive breast cancer through the HIF1α signaling
Abstract Breast cancer is the most common malignancy in women on a global scale. It can generally be divided into four main categories, of which estrogen receptor ER-positive breast cancer accounts for most breast cancer cases. RBCK1 protein is an E3 ubiquitin ligase containing the UBL, NZF, and RBR...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2022-12-01
|
| Series: | Cell Death and Disease |
| Online Access: | https://doi.org/10.1038/s41419-022-05473-6 |
| _version_ | 1811178993653645312 |
|---|---|
| author | Zhiguo Niu Jianing Fan Fengzhe Chen Huijie Yang Xin Li Ting Zhuang Chunlei Guo Qi Cao Jian Zhu Hui Wang Qingsong Huang |
| author_facet | Zhiguo Niu Jianing Fan Fengzhe Chen Huijie Yang Xin Li Ting Zhuang Chunlei Guo Qi Cao Jian Zhu Hui Wang Qingsong Huang |
| author_sort | Zhiguo Niu |
| collection | DOAJ |
| description | Abstract Breast cancer is the most common malignancy in women on a global scale. It can generally be divided into four main categories, of which estrogen receptor ER-positive breast cancer accounts for most breast cancer cases. RBCK1 protein is an E3 ubiquitin ligase containing the UBL, NZF, and RBR domains. It is well known to exhibit abnormal expression in breast tumors, making it a valuable diagnostic marker and drug target. Additionally, studies have confirmed that in breast cancer, about 25 to 40% of tumors appear as visible hypoxic regions, while in hypoxia, tumor cells can activate the hypoxia-inducing factor HIF1 pathway and widely activate the expression of downstream genes. Previous studies have confirmed that in the hypoxic environment of tumors, HIF1α promotes the remodeling of extracellular matrix, induces the recruitment of tumor-associated macrophages (TAM) and immunosuppression of allogeneic tumors, thereby influencing tumor recurrence and metastasis. This research aims to identify RBCK1 as an important regulator of HIF1α signaling pathway. Targeted therapy with RBCK1 could be a promising treatment strategy for ER-positive breast cancer. |
| first_indexed | 2024-04-11T06:27:22Z |
| format | Article |
| id | doaj.art-6eca799ada504c11859640cb9d98f766 |
| institution | Directory Open Access Journal |
| issn | 2041-4889 |
| language | English |
| last_indexed | 2024-04-11T06:27:22Z |
| publishDate | 2022-12-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Cell Death and Disease |
| spelling | doaj.art-6eca799ada504c11859640cb9d98f7662022-12-22T04:40:18ZengNature Publishing GroupCell Death and Disease2041-48892022-12-01131211110.1038/s41419-022-05473-6RBCK1 regulates the progression of ER-positive breast cancer through the HIF1α signalingZhiguo Niu0Jianing Fan1Fengzhe Chen2Huijie Yang3Xin Li4Ting Zhuang5Chunlei Guo6Qi Cao7Jian Zhu8Hui Wang9Qingsong Huang10Henan Key Laboratory of Immunology and Targeted Drugs, School of Laboratory Medicine, Xinxiang Medical UniversityHenan Key Laboratory of Immunology and Targeted Drugs, School of Laboratory Medicine, Xinxiang Medical UniversityHenan Key Laboratory of Immunology and Targeted Drugs, School of Laboratory Medicine, Xinxiang Medical UniversityHenan Key Laboratory of Immunology and Targeted Drugs, School of Laboratory Medicine, Xinxiang Medical UniversityHenan Key Laboratory of Immunology and Targeted Drugs, School of Laboratory Medicine, Xinxiang Medical UniversityHenan Key Laboratory of Immunology and Targeted Drugs, School of Laboratory Medicine, Xinxiang Medical UniversityHenan Key Laboratory of Immunology and Targeted Drugs, School of Laboratory Medicine, Xinxiang Medical UniversityHenan Key Laboratory of Immunology and Targeted Drugs, School of Laboratory Medicine, Xinxiang Medical UniversityDepartment of General Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong UniversityHenan Key Laboratory of Immunology and Targeted Drugs, School of Laboratory Medicine, Xinxiang Medical UniversityHenan Key Laboratory of Immunology and Targeted Drugs, School of Laboratory Medicine, Xinxiang Medical UniversityAbstract Breast cancer is the most common malignancy in women on a global scale. It can generally be divided into four main categories, of which estrogen receptor ER-positive breast cancer accounts for most breast cancer cases. RBCK1 protein is an E3 ubiquitin ligase containing the UBL, NZF, and RBR domains. It is well known to exhibit abnormal expression in breast tumors, making it a valuable diagnostic marker and drug target. Additionally, studies have confirmed that in breast cancer, about 25 to 40% of tumors appear as visible hypoxic regions, while in hypoxia, tumor cells can activate the hypoxia-inducing factor HIF1 pathway and widely activate the expression of downstream genes. Previous studies have confirmed that in the hypoxic environment of tumors, HIF1α promotes the remodeling of extracellular matrix, induces the recruitment of tumor-associated macrophages (TAM) and immunosuppression of allogeneic tumors, thereby influencing tumor recurrence and metastasis. This research aims to identify RBCK1 as an important regulator of HIF1α signaling pathway. Targeted therapy with RBCK1 could be a promising treatment strategy for ER-positive breast cancer.https://doi.org/10.1038/s41419-022-05473-6 |
| spellingShingle | Zhiguo Niu Jianing Fan Fengzhe Chen Huijie Yang Xin Li Ting Zhuang Chunlei Guo Qi Cao Jian Zhu Hui Wang Qingsong Huang RBCK1 regulates the progression of ER-positive breast cancer through the HIF1α signaling Cell Death and Disease |
| title | RBCK1 regulates the progression of ER-positive breast cancer through the HIF1α signaling |
| title_full | RBCK1 regulates the progression of ER-positive breast cancer through the HIF1α signaling |
| title_fullStr | RBCK1 regulates the progression of ER-positive breast cancer through the HIF1α signaling |
| title_full_unstemmed | RBCK1 regulates the progression of ER-positive breast cancer through the HIF1α signaling |
| title_short | RBCK1 regulates the progression of ER-positive breast cancer through the HIF1α signaling |
| title_sort | rbck1 regulates the progression of er positive breast cancer through the hif1α signaling |
| url | https://doi.org/10.1038/s41419-022-05473-6 |
| work_keys_str_mv | AT zhiguoniu rbck1regulatestheprogressionoferpositivebreastcancerthroughthehif1asignaling AT jianingfan rbck1regulatestheprogressionoferpositivebreastcancerthroughthehif1asignaling AT fengzhechen rbck1regulatestheprogressionoferpositivebreastcancerthroughthehif1asignaling AT huijieyang rbck1regulatestheprogressionoferpositivebreastcancerthroughthehif1asignaling AT xinli rbck1regulatestheprogressionoferpositivebreastcancerthroughthehif1asignaling AT tingzhuang rbck1regulatestheprogressionoferpositivebreastcancerthroughthehif1asignaling AT chunleiguo rbck1regulatestheprogressionoferpositivebreastcancerthroughthehif1asignaling AT qicao rbck1regulatestheprogressionoferpositivebreastcancerthroughthehif1asignaling AT jianzhu rbck1regulatestheprogressionoferpositivebreastcancerthroughthehif1asignaling AT huiwang rbck1regulatestheprogressionoferpositivebreastcancerthroughthehif1asignaling AT qingsonghuang rbck1regulatestheprogressionoferpositivebreastcancerthroughthehif1asignaling |